Literature DB >> 3034638

Down-regulation of atrial natriuretic peptide receptor and cyclic GMP response in cultured rat vascular smooth muscle cells.

Y Hirata, S Hirose, S Takata, Y Takagi, H Matsubara.   

Abstract

Treatment of cultured rat vascular smooth muscle cells with human atrial natriuretic peptide (hANP) or Met(O)12hANP caused a similar and marked reduction (approximately 80%) of ANP receptor number (down-regulation). A second challenge with hANP stimulated the accumulation of intracellular cGMP in the down-regulated cells to the same extent as in control cells. These data suggest that ANP receptor sites are functionally heterogenous, the more abundant site being uncoupled from guanylate cyclase but susceptible to down-regulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034638     DOI: 10.1016/0014-2999(87)90697-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Differential internalization and processing of atrial-natriuretic-factor B and C receptor in PC12 cells.

Authors:  A Rathinavelu; G E Isom
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

Review 2.  Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases.

Authors:  Johanne Tremblay; Richard Desjardins; David Hum; Jolanta Gutkowska; Pavel Hamet
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

3.  Increased cyclic guanosine monophosphate production and overexpression of atrial natriuretic peptide A-receptor mRNA in spontaneously hypertensive rats.

Authors:  J Tremblay; C Huot; R C Willenbrock; F Bayard; F Gossard; N Fujio; C Koch; O Kuchel; W Debinski; P Hamet
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 4.  Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes phosphoinositide hydrolysis, Ca(2+) release, and activation of protein kinase C.

Authors:  Kailash N Pandey
Journal:  Front Mol Neurosci       Date:  2014-08-22       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.